Business Description
Arvinas Inc
NAICS : 325412
SIC : 2834
ISIN : US04335A1051
Total Employee Number:
246Description
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 73.2 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.42 | |||||
Beneish M-Score | -0.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 40.1 | |||||
3-Year FCF Growth Rate | 9.6 | |||||
3-Year Book Growth Rate | -13.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -37.09 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -33.96 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.62 | |||||
9-Day RSI | 41.82 | |||||
14-Day RSI | 44.13 | |||||
3-1 Month Momentum % | -32.55 | |||||
6-1 Month Momentum % | -39.18 | |||||
12-1 Month Momentum % | -2.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.44 | |||||
Quick Ratio | 5.44 | |||||
Cash Ratio | 5.31 | |||||
Days Sales Outstanding | 19.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | -0.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -283.78 | |||||
Net Margin % | -247.54 | |||||
EBITDA Margin % | -278.19 | |||||
FCF Margin % | -287.36 | |||||
OCF Margin % | -284.23 | |||||
ROE % | -41.69 | |||||
ROA % | -26.86 | |||||
ROIC % | -208.02 | |||||
3-Year ROIIC % | -90.44 | |||||
ROC (Joel Greenblatt) % | -1742.45 | |||||
ROCE % | -37.92 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.36 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | 0.35 | |||||
EV-to-Forward-EBIT | 0.12 | |||||
EV-to-EBITDA | 0.36 | |||||
EV-to-Forward-EBITDA | 0.11 | |||||
EV-to-Revenue | -0.99 | |||||
EV-to-Forward-Revenue | 0.09 | |||||
EV-to-FCF | 0.34 | |||||
Price-to-GF-Value | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 1.4 | |||||
| Price-to-Net-Cash | 1.46 | |||||
Earnings Yield (Greenblatt) % | 285.71 | |||||
FCF Yield % | -49.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARVN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arvinas Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 89.4 | ||
| EPS (TTM) ($) | -3.32 | ||
| Beta | 2.5703 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 44.5 | ||
| 14-Day RSI | 44.13 | ||
| 14-Day ATR ($) | 0.394764 | ||
| 20-Day SMA ($) | 8.179 | ||
| 12-1 Month Momentum % | -2.24 | ||
| 52-Week Range ($) | 6.055 - 14.51 | ||
| Shares Outstanding (Mil) | 64.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arvinas Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arvinas Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 112 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 111 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 20 days | ||
| General meeting for 2026 | 2026-06-24 08:00 | 8.14 (+6.68%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 8.00 (-5.21%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 9.66 (-4.45%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 9.66 (-4.45%) | ||
| Guidance call for 2026 | 2026-03-11 | 13.83 (-3.42%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 11:00 | 13.37 (+1.21%) |
Show
Entries
Arvinas Inc Frequently Asked Questions
What is Arvinas Inc(ARVN)'s stock price today?
The current price of ARVN is $8.03. The 52 week high of ARVN is $14.51 and 52 week low is $6.06.
When is next earnings date of Arvinas Inc(ARVN)?
The next earnings date of Arvinas Inc(ARVN) is 2026-08-06 Est..
Does Arvinas Inc(ARVN) pay dividends? If so, how much?
Arvinas Inc(ARVN) does not pay dividend.
Guru Commentaries on NAS:ARVN
No articles.
Press Release
Articles on Arvinas Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers